RU2000129659A

RU2000129659A - CONDENSED THIENOPYRIMIDINES WITH INHIBITING PHOSPHODYESTERASE V ACTION

Info

Publication number: RU2000129659A
Application number: RU2000129659/04A
Authority: RU
Inventors: Рохус ЙОНАС; Пьер ШЕЛЛИНГ; Франц-Вернер КЛУКСЕН; Мария Кристадлер
Original assignee: Мерк Патент Гмбх
Priority date: 1998-04-29
Filing date: 1999-04-23
Publication date: 2003-01-27

Claims

1. The compounds of formula I

in which R ¹ , R ² each independently from each other denotes H, A, OA or Hal,
R ¹ and R ² together also denote alkylene with 3-5 C atoms, —O — CH ₂ —CH ₂ -, —CH ₂ —O — CH ₂ -, —O — CH ₂ —O— or —O — CH _2- CH ₂ -O-,
X denotes a monosubstituted substituent R ⁷ , R ⁴ , R ⁵ or R ⁶ ,
R ⁴ denotes a linear or branched alkylene with 1-10 C-atoms, where one or two CH ₂ groups can be replaced by -CH = CH groups,
R ⁵ denotes cycloalkyl or cycloalkylalkylene with 5-12 C-atoms,
R ⁶ is phenyl or phenylmethyl,
R ⁷ is COOH, COOA, CONH ₂ , CONHA, CON (A) ₂ or CN,
A denotes alkyl with 1-6 C atoms and
Hal is F, Cl, Br or I,
as well as their physiologically acceptable salts.

2. The compounds of formula I according to claim 1
(a) 3- [4- (3-chloro-4-methoxybenzylamino) benzo [4,5] thieno [2,3-d] pyrimidin-2-yl] propionic acid;
(b) 4- [4- (3,4-methylenedioxybenzylamino) benzo [4,5] thieno [2,3-d] pyrimidin-2-yl] butyric acid;
(c) 7- [4- (3,4-methylenedioxybenzylamino) benzo [4,5] thieno [2,3-d] pyrimidin-2-yl] heptanoic acid;
(d) 7- [4- (3-chloro-4-methoxybenzylamino) benzo [4,5] thieno [2,3-d] pyrimidin-2-yl] heptanoic acid;
(e) 5- [4- (3-chloro-4-methoxybenzylamino) benzo [4,5] thieno [2,3-d] pyrimidin-2-yl] valerianic acid;
(e) 2- {4- [4- (3-chloro-4-methoxybenzylamino) benzo [4,5] thieno [2,3-d] pyrimidin-2-yl] cyclohexyl-1-yl} acetic acid;
(g) 4- [4- (3,4-methylenedioxybenzylamino) benzo [4,5] thieno [2,3-d] pyrimidin-2-yl] cyclohexanecarboxylic acid;
(h) 4- [4- (3,4-methylenedioxybenzylamino) benzo [4,5] thieno [2,3-d] pyrimidin-2-yl] benzoic acid;
(i) 4- [4- (3,4-methylenedioxybenzylamino) benzo [4,5] thieno [2,3-d] pyrimidin-2-yl] phenylacetic acid;
as well as their physiologically acceptable salts.

3. A method of obtaining compounds of formula I according to claim 1, as well as their salts, characterized in that
a) a compound of formula II

where X has the above meanings;
L is Cl, Br, OH, SCH ₃ or a reactive esterified OH group,
react with a compound of formula III

where R ¹ and R ² have the above meanings, or
b) in a compound of formula I, one residue X is converted to another residue X, for example by hydrolysis of an ester group to a COOH group or by converting a COOH group to an amide or to a cyano group,
and / or that the compound of formula I is converted into one of its salts.

4. A method for producing pharmaceutical compositions, characterized in that an appropriate dosage form is prepared from a compound of formula I according to claim 1 and / or one of its physiologically acceptable salts together with at least one solid, liquid or semi-liquid carrier or excipient.

5. A pharmaceutical composition, characterized in that it contains at least one compound of formula I according to claim 1 and / or one of its physiologically acceptable salts.

6. The compounds of formula I according to claim 1 and their physiologically acceptable salts for combating diseases of the cardiovascular system and for the treatment and / or therapy of potency disorders.

7. Medicines of the formula I according to claim 1 and their physiologically acceptable salts as phosphodiesterase V inhibitors.

8. The use of compounds of formula I according to claim 1 and / or their physiologically acceptable salts for the manufacture of an appropriate drug.

9. The use of compounds of formula I according to claim 1 and / or their physiologically acceptable salts for the control of diseases.